Tissue Microarrays in Clinical Oncology

Seminars in Radiation Oncology

Volumn 18, Issue 2, 2008, Pages 89-97

  Voduc, David ^a   Kenney, Challayne ^b   Nielsen, Torsten O ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Genetic Pathology Evaluation Centre   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; MOLECULAR MARKER; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; DNA MICROARRAY; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE BIOPSY; MICROARRAY ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; TISSUE MICROARRAY; TREATMENT OUTCOME;

GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 39749091794     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.10.006     Document Type: Article

References (57)

1. Kononen J., Bubendorf L., and Kallioniemi A. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
2. Liu C.L., Montgomery K.D., and Natkunam Y. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol 18 (2005) 1641-1648
3. Hughes-Davies L., Huntsman D., and Ruas M. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115 (2003) 523-535
4. Moyano J.V., Evans J.R., and Chen F. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116 (2006) 261-270
5. Tomlins S.A., Rhodes D.R., and Perner S. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
6. Eerola H., Heikkila P., and Tamminen A. Histopathological features of breast tumours in BRCA1. BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 (2005) R93-R100
7. Palacios J., Honrado E., and Osorio A. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90 (2005) 5-14
8. Fan S.Q., Ma J., and Zhou J. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol 37 (2006) 593-605
9. Alonso S.R., Ortiz P., and Pollan M. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164 (2004) 193-203
10. Boddy J.L., Fox S.B., and Han C. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a. HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11 (2005) 7658-7663
11. Hawk E.T., and Levin B. Colorectal cancer prevention. J Clin Oncol 23 (2005) 378-391
12. Kerlikowske K., Grady D., and Rubin S.M. Efficacy of screening mammography. A meta-analysis. JAMA 273 (1995) 149-154
13. Hammoud Z.T., Badve S., and Saxena R. A novel biomarker for the detection of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 133 (2007) 82-87
14. Stewart J.M., Fleshner N., and Cole H. Comparison of annexin II, p63 and AMACR immunoreactivity in prostatic tissue: A tissue microarray study. J Clin Pathol 60 (2007) 773-780
15. Mhawech-Fauceglia P., Herrmann F., and Bshara W. FLI-1 Expression in 4323 malignant and benign tumours: A multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol 60 (2007) 694-700
16. Kambham N., Kong C., and Longacre T.A. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: A tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 13 (2005) 304-310
17. Owens S.R., and Greenson J.K. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol 31 (2007) 285-290
18. Au N.H., Gown A.M., and Cheang M. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12 (2004) 240-247
19. Hans C.P., Weisenburger D.D., and Greiner T.C. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
20. Terry J., Saito T., and Subramanian S. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31 (2007) 240-246
21. Stephenson A.J., and Kattan M.W. Nomograms for prostate cancer. BJU Int 98 (2006) 39-46
22. Ravdin P.M., Siminoff L.A., and Davis G.J. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
23. van de Rijn M., and Gilks C.B. Applications of microarrays to histopathology. Histopathology 44 (2004) 97-108
24. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
25. Banham A.H., Connors J.M., and Brown P.J. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11 (2005) 1065-1072
26. Sorlie T., Tibshirani R., and Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
27. Perou C.M., Sorlie T., and Eisen M.B. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
28. Nielsen T.O., Hsu F.D., and Jensen K. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
29. Psyrri A., Yu Z., and Weinberger P.M. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11 (2005) 5856-5862
30. Yu Z., Weinberger P.M., and Haffty B.G. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 11 (2005) 1160-1166
31. Deeb G., Wang J., and Ramnath N. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17 (2004) 430-439
32. Tan D., Li Q., and Deeb G. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34 (2003) 597-604
33. Parikh R.R., Yang Q., and Haffty B.G. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 109 (2007) 566-573
34. Cho E.I., Kowalski D.P., and Sasaki C.T. Tissue microarray analysis reveals prognostic significance of COX-2 expression for local relapse in T1-2N0 larynx cancer treated with primary radiation therapy. Laryngoscope 114 (2004) 2001-2008
35. Paik S., Tang G., and Shak S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
36. Paik S., Shak S., and Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
37. Howell A., Cuzick J., and Baum M. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
38. Dowsett M. Biomarker investigations from the ATAC trial: The role of TA01. Breast Cancer Res Treat 87 suppl 1 (2004) S11-S18
39. Dowsett M., and Allred D.C. Relationship between quantitative ER and PgR and Her2 status with recurrence in the ATAC trial (2006) Presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 14-17
40. Keyomarsi K., Tucker S.L., and Buchholz T.A. Cyclin E and survival in patients with breast cancer. N Engl J Med 347 (2002) 1566-1575
41. Porter P.L., Barlow W.E., and Yeh I.T. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98 (2006) 1723-1731
42. Wang L., and Shao Z.M. Cyclin e expression and prognosis in breast cancer patients: A meta-analysis of published studies. Cancer Invest 24 (2006) 581-587
43. Bubendorf L., Nocito A., and Moch H. Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J Pathol 195 (2001) 72-79
44. Fitzgibbons P.L., Murphy D.A., and Dorfman D.M. Interlaboratory comparison of immunohistochemical testing for HER2: Results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med 130 (2006) 1440-1445
45. Dorfman D.M., Bui M.M., and Tubbs R.R. The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: A College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med 130 (2006) 779-782
46. de Jong D., Rosenwald A., and Chhanabhai M. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25 (2007) 805-812
47. Cheang M.C., Treaba D.O., and Speers C.H. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24 (2006) 5637-5644
48. Selvarajan S., Tan S.Y., and Sii L.H. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: Is there concordance between standard sections and tissue microarrays?. Pathology 38 (2006) 316-320
49. O'Grady A., Flahavan C.M., and Kay E.W. HER-2 analysis in tissue microarrays of archival human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 11 (2001) 177-182
50. Sapino A., Marchio C., and Senetta R. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449 (2006) 288-296
51. Horvath L., and Henshall S. The application of tissue microarrays to cancer research. Pathology 33 (2001) 125-129
52. Simon R., and Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 30 (2002) 1365-1372
53. Torhorst J., Bucher C., and Kononen J. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
54. Leversha M.A., Fielding P., and Watson S. Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarrays. J Pathol 200 (2003) 610-619
55. Jourdan F., Sebbagh N., and Comperat E. Tissue microarray technology: Validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443 (2003) 115-121
56. Hoos A., and Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest 81 (2001) 1331-1338
57. Mirlacher M., Kasper M., and Storz M. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17 (2004) 1414-1420